A detailed history of Acadian Asset Management LLC transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 1,304,511 shares of KRON stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,304,511
Previous 1,229,910 6.07%
Holding current value
$1.12 Million
Previous $1.52 Million 14.5%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.92 - $1.5 $68,632 - $111,901
74,601 Added 6.07%
1,304,511 $1.3 Million
Q2 2024

Aug 06, 2024

BUY
$0.73 - $1.38 $332,406 - $628,384
455,351 Added 58.79%
1,229,910 $1.52 Million
Q1 2024

May 10, 2024

BUY
$1.02 - $1.3 $115,890 - $147,703
113,618 Added 17.19%
774,559 $1.01 Million
Q4 2023

Feb 13, 2024

BUY
$0.75 - $1.49 $34,497 - $68,534
45,996 Added 7.48%
660,941 $825,000
Q3 2023

Nov 13, 2023

BUY
$1.23 - $2.25 $45,398 - $83,045
36,909 Added 6.39%
614,945 $798,000
Q2 2023

Aug 07, 2023

BUY
$1.24 - $1.92 $126,156 - $195,338
101,739 Added 21.36%
578,036 $993,000
Q1 2023

May 11, 2023

BUY
$1.34 - $2.62 $94,433 - $184,639
70,473 Added 17.37%
476,297 $694,000
Q4 2022

Feb 14, 2023

BUY
$1.44 - $3.44 $284,024 - $678,502
197,239 Added 94.56%
405,824 $657,000
Q3 2022

Nov 14, 2022

BUY
$3.35 - $5.55 $205,267 - $340,070
61,274 Added 41.59%
208,585 $697,000
Q2 2022

Aug 09, 2022

BUY
$3.12 - $7.52 $448,481 - $1.08 Million
143,744 Added 4029.83%
147,311 $536,000
Q1 2022

May 12, 2022

BUY
$6.26 - $14.42 $22,329 - $51,436
3,567 New
3,567 $25,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $48.8M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.